Literature DB >> 19449434

Interstitial 11q deletion derived from a maternal ins(4;11)(p14;q24.2q25): a patient report and review.

Laura J C M Van Zutven1, Yolande van Bever, Carolien C M Van Nieuwland, Gido C M Huijbregts, Diane Van Opstal, Anne R M von Bergh, Linda J A Corel, Dick Tibboel, Cokkie H Wouters, Pino J Poddighe.   

Abstract

We present a family with multiple cytogenetic abnormalities, identified through a girl with several dysmorphic features and cardiac problems, suspected for Jacobsen syndrome. Cytogenetic analysis showed a 46,XX,del(11)(qter) karyotype, which was confirmed by fluorescence in situ hybridization (FISH). Cytogenetic investigation of the parents showed a chromosome aberration in both: the father had a t(11;12)(p13;q22) translocation and the mother was carrier of an ins(4;11)(p14;q24q25). FISH analysis with an 11q-subtelomeric probe from the second-generation telomere clone set and BACs from 11q24-q25 suggested a complex maternal rearrangement. However, subsequent array analysis showed a single interstitial deletion in the proband, derived from the maternal insertion. The aberrant karyotypes in both parents implicated an increased risk of unbalanced fetal chromosome composition, thus high risk for a child with multiple congenital abnormalities. Therefore, during the next pregnancy, the couple opted for prenatal diagnosis by means of amniocentesis. An interphase FISH strategy for uncultured amniotic fluid cells predicted two possible unbalanced fetal chromosome constitutions. Karyotyping of cultured amniotic cells confirmed one of the predicted unbalanced cytogenetic options, demonstrating the value of a fast interphase strategy for parents who both are carriers of a chromosomal abnormality. In addition, we present an overview of patients with Jacobsen syndrome and an interstitial 11q deletion reported thus far in literature.

Entities:  

Mesh:

Year:  2009        PMID: 19449434     DOI: 10.1002/ajmg.a.32714

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

1.  Parental insertional balanced translocations are an important cause of apparently de novo CNVs in patients with developmental anomalies.

Authors:  Beata A Nowakowska; Nicole de Leeuw; Claudia Al Ruivenkamp; Birgit Sikkema-Raddatz; John A Crolla; Reinhilde Thoelen; Marije Koopmans; Nicolette den Hollander; Arie van Haeringen; Anne-Marie van der Kevie-Kersemaekers; Rolph Pfundt; Hanneke Mieloo; Ton van Essen; Bert B A de Vries; Andrew Green; Willie Reardon; Jean-Pierre Fryns; Joris R Vermeesch
Journal:  Eur J Hum Genet       Date:  2011-09-14       Impact factor: 4.246

Review 2.  Genetics of familial forms of thrombocytopenia.

Authors:  Carlo L Balduini; Anna Savoia
Journal:  Hum Genet       Date:  2012-08-11       Impact factor: 4.132

3.  Jacobsen Syndrome: Surgical Complications due to Unsuspected Diagnosis, the Importance of Molecular Studies in Patients with Craniosynostosis.

Authors:  Etzalli P Linares Chávez; Jaime Toral López; Juan M Valdés Miranda; Luz M González Huerta; Adrian Perez Cabrera; María Del Refugio Rivera Vega; Olga M Messina Baas; Sergio A Cuevas-Covarrubias
Journal:  Mol Syndromol       Date:  2015-12-18

4.  de novo interstitial deletions at the 11q23.3-q24.2 region.

Authors:  Jiasun Su; Rongyu Chen; Jingsi Luo; Xin Fan; Chunyun Fu; Jin Wang; Sheng He; Xuyun Hu; ShuJie Zhang; Shang Yi; Shaoke Chen; Yiping Shen
Journal:  Mol Cytogenet       Date:  2016-05-05       Impact factor: 2.009

5.  Distal Deletion of Chromosome 11q Encompassing Jacobsen Syndrome without Platelet Abnormality.

Authors:  Frenny J Sheth; Chaitanya Datar; Joris Andrieux; Anand Pandit; Darshana Nayak; Mizanur Rahman; Jayesh J Sheth
Journal:  Clin Med Insights Pediatr       Date:  2014-09-17

6.  Bone marrow failure may be caused by chromosome anomalies exerting effects on RUNX1T1 gene.

Authors:  R Valli; L Vinti; A Frattini; M Fabbri; G Montalbano; C Olivieri; A Minelli; F Locatelli; F Pasquali; E Maserati
Journal:  Mol Cytogenet       Date:  2018-01-11       Impact factor: 2.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.